Downloads: 67

Files in This Item:
File Description SizeFormat 
s41598-023-32426-6.pdf1.43 MBAdobe PDFView/Open
Full metadata record
DC FieldValueLanguage
dc.contributor.authorShimazu, Yutakaen
dc.contributor.authorKanda, Junyaen
dc.contributor.authorKosugi, Satoruen
dc.contributor.authorIto, Tomokien
dc.contributor.authorKaneko, Hitomien
dc.contributor.authorImada, Kazunorien
dc.contributor.authorShimura, Yujien
dc.contributor.authorFuchida, Shin-ichien
dc.contributor.authorFukushima, Kentaroen
dc.contributor.authorTanaka, Hirokazuen
dc.contributor.authorYoshihara, Satoshien
dc.contributor.authorOhta, Kensukeen
dc.contributor.authorUoshima, Nobuhikoen
dc.contributor.authorYagi, Hideoen
dc.contributor.authorShibayama, Hirohikoen
dc.contributor.authorYamamura, Ryosukeen
dc.contributor.authorTanaka, Yasuhiroen
dc.contributor.authorUchiyama, Hitojien
dc.contributor.authorOnda, Yoshiyukien
dc.contributor.authorAdachi, Yokoen
dc.contributor.authorHanamoto, Hitoshien
dc.contributor.authorTakahashi, Ryoichien
dc.contributor.authorMatsuda, Mitsuhiroen
dc.contributor.authorMiyoshi, Takashien
dc.contributor.authorTakakuwa, Teruhitoen
dc.contributor.authorHino, Masayukien
dc.contributor.authorHosen, Naokien
dc.contributor.authorNomura, Shosakuen
dc.contributor.authorShimazaki, Chihiroen
dc.contributor.authorMatsumura, Itaruen
dc.contributor.authorTakaori-Kondo, Akifumien
dc.contributor.authorKuroda, Junyaen
dc.contributor.alternative島津, 裕ja
dc.contributor.alternative諫田, 淳也ja
dc.contributor.alternative髙折, 晃史ja
dc.date.accessioned2023-06-21T05:26:08Z-
dc.date.available2023-06-21T05:26:08Z-
dc.date.issued2023-03-29-
dc.identifier.urihttp://hdl.handle.net/2433/283384-
dc.description.abstractNovel therapeutic drugs have dramatically improved the overall survival of patients with multiple myeloma. We sought to identify the characteristics of patients likely to exhibit a durable response to one such drug, elotuzumab, by analyzing a real-world database in Japan. We analyzed 179 patients who underwent 201 elotuzumab treatments. The median time to next treatment (TTNT) with the 95% confidence interval was 6.29 months (5.18-9.20) in this cohort. Univariate analysis showed that patients with any of the following had longer TTNT: no high risk cytogenic abnormalities, more white blood cells, more lymphocytes, non-deviated κ/λ ratio, lower β2 microglobulin levels (B2MG), fewer prior drug regimens, no prior daratumumab use and better response after elotuzumab treatment. A multivariate analysis showed that TTNT was longer in patients with more lymphocytes (≥ 1400/μL), non-deviated κ/λ ratio (0.1-10), lower B2MG (< 5.5 mg/L) and no prior daratumumab use. We proposed a simple scoring system to predict the durability of the elotuzumab treatment effect by classifying the patients into three categories based on their lymphocyte counts (0 points for ≥ 1400/μL and 1 point for < 1400/μL) and κ/λ ratio (0 points for 0.1-10 and 1 point for < 0.1 or ≥ 10) or B2MG (0 points for < 5.5 mg/L and 1 point for ≥ 5.5 mg/L). The patients with a score of 0 showed significantly longer TTNT (p < 0.001) and better survival (p < 0.001) compared to those with a score of 1 or 2. Prospective cohort studies of elotuzumab treatment may be needed to validate the usefulness of our new scoring system.en
dc.language.isoeng-
dc.publisherSpringer Natureen
dc.rights© The Author(s) 2023en
dc.rightsThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/-
dc.subjectImmunotherapyen
dc.subjectLymphocytesen
dc.subjectPredictive markersen
dc.subjectTranslational researchen
dc.subjectTumour immunologyen
dc.titleEfficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulinen
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleScientific Reportsen
dc.identifier.volume13-
dc.relation.doi10.1038/s41598-023-32426-6-
dc.textversionpublisher-
dc.identifier.artnum5159-
dc.identifier.pmid36991096-
dcterms.accessRightsopen access-
dc.identifier.eissn2045-2322-
Appears in Collections:Journal Articles

Show simple item record

Export to RefWorks


Export Format: 


This item is licensed under a Creative Commons License Creative Commons